SC
NTLA icon

SummitTX Capital’s Intellia Therapeutics NTLA Stock Holding History

SummitTX Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,287
Closed -$155K – 908
2025
Q4 		$155K Buy
+17,287
New +$238K ﹤0.01% 655
2025
Q2 		– Sell
-11,258
Closed -$80K – 944
2025
Q1 		$80K Buy
+11,258
New +$114K ﹤0.01% 764

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SummitTX Capital's NTLA Position: Q1 2026 in Review

SummitTX Capital sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 17,287 shares — an estimated $155K sold.

SummitTX Capital first reported a position in NTLA in Q1 2025 and held it in 2 quarters. The position peaked at $155K in Q4 2025. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • SummitTX Capital reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SummitTX Capital sold 17,287 Intellia Therapeutics shares in Q1 2026, an estimated $155K.
  • SummitTX Capital first reported a position in Intellia Therapeutics in Q1 2025 and held it in 2 quarters.
  • SummitTX Capital's Intellia Therapeutics position peaked at $155K in Q4 2025.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.